Difference between revisions of "The Compendium of Cancer Genome Aberrations"
| [unchecked revision] | [unchecked revision] |
| Line 46: | Line 46: | ||
<br> | <br> | ||
<br> | <br> | ||
| − | [[File:CGC logo only.png|100px|link=Main_Page]]<span style=" | + | [[File:CGC logo only.png|100px|link=Main_Page]]<span style="margin-top: -10px;"> '''CGC Workgroups Recurrent Loci Tables'''</span><span style="display: block; margin-top: -50px; margin-left: 105px;"> [[AML Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray|AML]] | [[MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alterations Detected by Chromosomal Microarray|MDS/MPN]] | [[CLL Tables: Regions of Recurrent Copy Number Change and CN-LOH|CLL]] | [[Recurrent Genomic Alterations in Pediatric and Adult Central Nervous System Tumors Detected by Chromosomal Microarray|CNS Tumors]] | [[Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations|Plasma Cell Neoplasms]] | [[Breast Cancer Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray|Breast Cancer]] | [[Renal Cell Neoplasia Tables: Recurrent Cytogenomic Alterations|Renal Neoplasia]]</span> |
<br> | <br> | ||
<br> | <br> | ||
Revision as of 08:02, 28 April 2021
Welcome to the Compendium of Cancer Genome Aberrations (CCGA)! The CCGA is a collaborative effort to document and describe chromosome and other genomic abnormalities in cancer structured based on current WHO classification. The Wiki style interface allows for real-time editing and content sharing within our genetics community. This resource is sponsored and supported by the Cancer Genomics Consortium (CGC) and contributed to by colleagues with an interest in clinical cytogenetics, molecular genetics and genomics in cancer.
- Join the CCGA community! If you would like to contribute as an author, please complete a few brief questions on our Volunteer Form.
- Contact us for more information or suggestions for updates.
- Meet our Editorial Leadership, CCGA Workgroup Members and Communications Liaison.
- For contributors, we've created a Video Tutorial demonstrating how to add content to the CCGA. Please also refer to helpful Author Instructions.
- Become a part of our Twitter family for the latest updates @ccgawiki.
Diseases A
| B | C | D | E | F
| G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U
| V | W | X | Y | Z
Structural Abnormalities 1
| 2 | 3 | 4
| 5 | 6
| 7 | 8 | 9
| 10 | 11 | 12
| 13 | 14 | 15
| 16 | 17 | 18
| 19 | 20 | 21
| 22 | X | Y
Cancer Genes A
| B | C | D | E | F
| G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U
| V | W | X | Y | Z
Cancer Genomes Hematologic and Lymphoid | Solid Tumors | CNS | Pediatric
CGC Workgroups Recurrent Loci Tables AML | MDS/MPN | CLL | CNS Tumors | Plasma Cell Neoplasms | Breast Cancer | Renal Neoplasia
Notice and Disclaimer/Limitation of Liability of Resource Use
Data and information obtained from the Cancer Genomics Consortium (CGC) and the Compendium of Cancer Genome Aberrations (CCGA) is provided as an educational resource only. These data are provided on an "AS IS" basis, without representation or warranty of any kind, including without limitation the warranties of merchantability, fitness for a particular purpose and non-infringement. Availability of this data and information does not constitute scientific publication. Data and/or information may contain errors or be incomplete.
The CGC, CCGA and all participating entities make no representation or warranty, express or implied, including without limitation any warranties of merchantability or fitness for a particular purpose or warranties as to the identity or ownership of data or information, the quality, accuracy or completeness of data or information, or that the use of such data or information will not infringe any patent, intellectual property or proprietary rights of any party.
The CGC and CCGA shall not be liable for any claim for any and all loss, harm, illness or other damage or injury arising from access to or use of data or information howsoever caused, including without limitation, any direct, indirect, incidental, exemplary, special or consequential damages, even if advised of the possibility of such damages. The data and information obtained from the Cytogenomics Array Group database shall not be used as a substitute for the user's skills, expertise and experience.